Metastatic castration-resistant prostate cancer
Conditions
Brief summary
Radiographic progression-free survival.
Detailed description
Overall survival., Time to symptomatic/clinical progression., Time to PSA progression (defined according to PCWG3)., Event-free survival (EFS) – event being defined as one of the following: - death from any cause - presence of radiographic progression and symptomatic/clinical progression; - presence of radiographic progression and PSA progression; - presence of symptomatic/clinical progression and PSA progression, Objective response rate according to RECIST., PSA response (30%, 50%, 90% and best)., Duration of PSA response (50%)., AEs.
Interventions
DRUGCabazitaxel Accord 20 mg/ml concentrate for solution for infusion
DRUGLynparza 150 mg film-coated tablets
DRUGBAY 1841788
Sponsors
Swiss Group for Clinical Cancer Research
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiographic progression-free survival. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival., Time to symptomatic/clinical progression., Time to PSA progression (defined according to PCWG3)., Event-free survival (EFS) – event being defined as one of the following: - death from any cause - presence of radiographic progression and symptomatic/clinical progression; - presence of radiographic progression and PSA progression; - presence of symptomatic/clinical progression and PSA progression, Objective response rate according to RECIST., PSA response (30%, 50%, 90% and best)., Duration of PSA response (50%)., AEs. | — |
Countries
Spain
Outcome results
None listed